211 reports of this reaction
2.6% of all GUANFACINE HYDROCHLORIDE reports
#3 most reported adverse reaction
SOMNOLENCE is the #3 most commonly reported adverse reaction for GUANFACINE HYDROCHLORIDE, manufactured by Amneal Pharmaceuticals LLC. There are 211 FDA adverse event reports linking GUANFACINE HYDROCHLORIDE to SOMNOLENCE. This represents approximately 2.6% of all 8,032 adverse event reports for this drug.
Patients taking GUANFACINE HYDROCHLORIDE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for GUANFACINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for GUANFACINE HYDROCHLORIDE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 211 FDA reports for GUANFACINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 2.6% of all adverse event reports for GUANFACINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience somnolence while taking GUANFACINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.